Comparative Pharmacology
Head-to-head clinical analysis: CADUET versus ISOPTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CADUET versus ISOPTIN.
CADUET vs ISOPTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amlodipine: Dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, causing vasodilation and reduced peripheral vascular resistance. Atorvastatin: HMG-CoA reductase inhibitor that competitively inhibits the conversion of HMG-CoA to mevalonate, reducing cholesterol synthesis in the liver.
Verapamil inhibits calcium ion influx across cardiac and vascular smooth muscle cells, blocking L-type calcium channels, leading to vasodilation and reduced myocardial contractility and conduction velocity.
CADUET (amlodipine/atorvastatin) is available as tablets of 2.5/10, 2.5/20, 2.5/40, 5/10, 5/20, 5/40, 5/80, 10/10, 10/20, 10/40, and 10/80 mg amlodipine/atorvastatin. Initial dose depends on current antihypertensive and lipid-lowering therapy. Usual starting dose is 5/10 mg orally once daily; titrate at intervals of 2-4 weeks based on blood pressure and LDL-C goals. Maximum daily dose: amlodipine 10 mg; atorvastatin 80 mg.
Initial dose: 80-120 mg orally three times daily; sustained-release: 120-240 mg orally once daily. IV: 5-10 mg slow IV push over 2 minutes, may repeat after 15-30 minutes. Maximum daily oral dose: 480 mg.
None Documented
None Documented
Amlodipine: terminal half-life 30-50 h (enables once-daily dosing). Atorvastatin: terminal half-life ~14 h, but active metabolites (ortho- and para-hydroxy atorvastatin) have half-life 20-30 h; clinically, pharmacodynamic half-life (HMG-CoA reductase inhibition) is ~20-30 h.
Terminal elimination half-life: 4.5-12 hours (mean 8 hours); increases with hepatic impairment or cirrhosis
Amlodipine: 60% renal (metabolites), 20-25% biliary/fecal. Atorvastatin: 1% renal (unchanged), 90% biliary/fecal (≥70% as metabolites).
Renal (70% as metabolites, 3-5% unchanged); biliary/fecal (25%)
Category C
Category C
Calcium Channel Blocker + HMG-CoA Reductase Inhibitor
Calcium Channel Blocker